Ovarian Hyperstimulation Syndrome Using Calcium Infusion

Ovarian Hyper Stimulation Syndrome Using Calcium Infusion

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05198128

Enrollment

200

Registered

2022-01-20

Start date

2022-03-01

Completion date

2023-05-10

Last updated

2022-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ovarian Hyperstimulation Syndrome

Keywords

OHSS, calcium infusion, IVF, ICSI

Brief summary

the incidence of OHSS and clinical outcomes after calcium IV infusion in high-risk women undergoing ART

Detailed description

Among assisted reproductive technologies (ART), ovarian hyperstimulation syndrome (OHSS) is a serious iatrogenic complication affects up to 30% of women undergoing ART and caries high risks of morbidity and mortality. Women with age younger than 35 years, those with history of polycystic ovary syndrome (PCOS), or having a history of previous OHSS are more susceptible to develop OHSS

Interventions

DRUGCalcium intravenous infsuion

intravenous infusion of 10 % calcium gluconate 10 mL in 200 mL of physiologic saline on the day of ovum pickup, day 1,day 2, and day 3 after ovum pickup were administered in study group. Intravenous infusion was performed within 30 minutes

DRUG0.9 % saline

0.9 % saline

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Intervention model description

Calcium for Prevention of Ovarian Hyperstimulation Syndrome (OHSS)

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 45 Years

Healthy volunteers

Inclusion criteria

\- infertile women aged 20 to 38 years. BMI ranged from 18 to 40. serum FSH within normal limits( 1-12IU /l) presented with ovarian response suggestive of being at risk of developing OHSS because of the presence of at least 15 follicles of 10 mm or greater on the day of hCG administration.

Exclusion criteria

* endocrinopathies. a systemic disease. and Insulin-dependent diabetes Thyroid disease using any medication (e.g., insulin-sensitizing drugs and GnRH antagonists. patients need coasting for high risk of OHSS. patients need cycle cancellation. severe male infertility requiring testicular sperm extraction.

Design outcomes

Primary

Measure	Time frame	Description
OHSS rate	one year	ovarain hyperstimulation syndrome

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026